Case Report: Hepatocellular adenoma due to long-term oral stanozolol administration
This article presents a case of a 15-year-old male with a 6-year history of aplastic anemia treated with long-term oral stanozolol to promote hematopoiesis. Throughout this period, he underwent regular outpatient follow-up assessments of blood and liver function parameters. While abnormal liver func...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1654316/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849233670814040064 |
|---|---|
| author | Ya-Nan Qin Chang-Ming Tao Tian-Tian Guo Jing-Jing Liu Wei-Chang Luan Chun-Hua Liu |
| author_facet | Ya-Nan Qin Chang-Ming Tao Tian-Tian Guo Jing-Jing Liu Wei-Chang Luan Chun-Hua Liu |
| author_sort | Ya-Nan Qin |
| collection | DOAJ |
| description | This article presents a case of a 15-year-old male with a 6-year history of aplastic anemia treated with long-term oral stanozolol to promote hematopoiesis. Throughout this period, he underwent regular outpatient follow-up assessments of blood and liver function parameters. While abnormal liver function was recorded on several occasions and treated with oral hepatoprotective drugs, no abdominal imaging test was conducted. On this occasion, the patient was admitted to hospital with abdominal pain. Abdominal imaging revealed a liver tumor of undetermined nature. A diagnosis of β-catenin-activated hepatocellular adenoma was subsequently confirmed via hepatic perforation biopsy. Considering the high bleeding risk, transcatheter hepatic artery embolization was performed as a preventative measure. Stanozolol was discontinued immediately after diagnosis and replaced with platelet-boosting therapy using romiplostim. A repeat abdominal CT scan performed 4 months after discontinuation of the drug showed a significant reduction in lesion size, which continued to be closely monitored. Hepatocellular adenoma is a rare clinical scenario. This case, supported by complete data and gold-standard pathologic diagnosis, provided valuable insights, suggesting that patients on long-term androgen therapy with aplastic anemia constituted a high-risk group for hepatocellular adenoma, and highlighted the need to optimize management strategies. |
| format | Article |
| id | doaj-art-5a85ba02fb784e24b9ec8de2c02008d1 |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-5a85ba02fb784e24b9ec8de2c02008d12025-08-20T04:14:18ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-08-011210.3389/fmed.2025.16543161654316Case Report: Hepatocellular adenoma due to long-term oral stanozolol administrationYa-Nan Qin0Chang-Ming Tao1Tian-Tian Guo2Jing-Jing Liu3Wei-Chang Luan4Chun-Hua Liu5Department of Infectious Diseases, Liaocheng People's Hospital, Liaocheng, ChinaDepartment of Infectious Diseases, Liaocheng People's Hospital, Liaocheng, ChinaImaging Department, Liaocheng People's Hospital, Liaocheng, ChinaDepartment of Infectious Diseases, Liaocheng People's Hospital, Liaocheng, ChinaEmergency Department, Liaocheng People's Hospital, Liaocheng, ChinaDepartment of Infectious Diseases, Liaocheng People's Hospital, Liaocheng, ChinaThis article presents a case of a 15-year-old male with a 6-year history of aplastic anemia treated with long-term oral stanozolol to promote hematopoiesis. Throughout this period, he underwent regular outpatient follow-up assessments of blood and liver function parameters. While abnormal liver function was recorded on several occasions and treated with oral hepatoprotective drugs, no abdominal imaging test was conducted. On this occasion, the patient was admitted to hospital with abdominal pain. Abdominal imaging revealed a liver tumor of undetermined nature. A diagnosis of β-catenin-activated hepatocellular adenoma was subsequently confirmed via hepatic perforation biopsy. Considering the high bleeding risk, transcatheter hepatic artery embolization was performed as a preventative measure. Stanozolol was discontinued immediately after diagnosis and replaced with platelet-boosting therapy using romiplostim. A repeat abdominal CT scan performed 4 months after discontinuation of the drug showed a significant reduction in lesion size, which continued to be closely monitored. Hepatocellular adenoma is a rare clinical scenario. This case, supported by complete data and gold-standard pathologic diagnosis, provided valuable insights, suggesting that patients on long-term androgen therapy with aplastic anemia constituted a high-risk group for hepatocellular adenoma, and highlighted the need to optimize management strategies.https://www.frontiersin.org/articles/10.3389/fmed.2025.1654316/fullaplastic anemiastanozololandrogenscase reporthepatocellular adenoma |
| spellingShingle | Ya-Nan Qin Chang-Ming Tao Tian-Tian Guo Jing-Jing Liu Wei-Chang Luan Chun-Hua Liu Case Report: Hepatocellular adenoma due to long-term oral stanozolol administration Frontiers in Medicine aplastic anemia stanozolol androgens case report hepatocellular adenoma |
| title | Case Report: Hepatocellular adenoma due to long-term oral stanozolol administration |
| title_full | Case Report: Hepatocellular adenoma due to long-term oral stanozolol administration |
| title_fullStr | Case Report: Hepatocellular adenoma due to long-term oral stanozolol administration |
| title_full_unstemmed | Case Report: Hepatocellular adenoma due to long-term oral stanozolol administration |
| title_short | Case Report: Hepatocellular adenoma due to long-term oral stanozolol administration |
| title_sort | case report hepatocellular adenoma due to long term oral stanozolol administration |
| topic | aplastic anemia stanozolol androgens case report hepatocellular adenoma |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1654316/full |
| work_keys_str_mv | AT yananqin casereporthepatocellularadenomaduetolongtermoralstanozololadministration AT changmingtao casereporthepatocellularadenomaduetolongtermoralstanozololadministration AT tiantianguo casereporthepatocellularadenomaduetolongtermoralstanozololadministration AT jingjingliu casereporthepatocellularadenomaduetolongtermoralstanozololadministration AT weichangluan casereporthepatocellularadenomaduetolongtermoralstanozololadministration AT chunhualiu casereporthepatocellularadenomaduetolongtermoralstanozololadministration |